Key Highlights
- AffyImmune Therapeutics announces the appointment of Rick Rutter, Ph.D., and Jorge Nieva, M.D., to its Board of Directors.
- Appointments bolster AffyImmune’s AIC100 CAR T cell therapy development for advanced thyroid cancers and non-small cell lung cancer (NSCLC).
- Rutter and Nieva bring decades of experience in CMC regulatory strategy and clinical oncology.
- AffyImmune’s AIC100 is nearing completion of Phase 1 trials for thyroid cancer and moving toward Phase 2 for NSCLC.
Source: Business Wire
Notable Quotes
- “I am delighted to join AffyImmune’s Board and to work with the management team to bring industry-best CMC and supply chain practices, and ready AIC100 for registrational trials and commercial launch.” — Rick Rutter, Ph.D., Former Executive Vice President, Biotherapeutics Pharmaceutical Sciences at Pfizer; Expert Consultant
- “Joining AffyImmune’s Board of Directors is an exciting opportunity to contribute to the expansion of AIC100 beyond advanced thyroid cancers, into larger indications such as NSCLC.” — Jorge Nieva, M.D., Associate Professor of Clinical Medicine at Keck School of Medicine, University of Southern California
SoHC's Take
AffyImmune’s strategic appointments of Rick Rutter, Ph.D., and Jorge Nieva, M.D., signal a pivotal moment for the company as it progresses its innovative CAR T cell therapy, AIC100, toward advanced clinical trials. These new board members not only enhance the company’s expertise in regulatory strategy and oncology but also strengthen its ability to address significant unmet medical needs in thyroid cancer and NSCLC. This expansion marks a crucial step for AffyImmune as it readies AIC100 for commercialization, advancing toward transforming solid tumor treatment landscapes.
Heading
Key Highlights Shore Capital Partners launches Agentis Longevity to lead the longevity healthcare sector. Jimmy St Louis named CEO, bringing expertise from Regenerative Medicine ...
Key Highlights Nymbl Systems announces strategic partnership with Frontier Growth to accelerate growth and innovation. Frontier Growth brings 25+ years of growth equity expertise to ...
Key Highlights Launch of fingertip blood collection technology using BD’s MiniDraw™ and Babson’s BetterWay for U.S. health systems. Revolutionizes access with fewer ...
Key Highlights Anatomy Financial raises $19M in Series A funding, led by Canapi Ventures. Neil Underwood (Canapi) and Nicole Quinn ...
Key Highlights Wendy Barnes to assume role as GoodRx CEO on January 1, 2025. Brings 30+ years of leadership in pharmacy and healthcare benefit industries. Former CEO of RxBenefits and President of Express ...
Key Highlights Mike Butler, former Providence president, joins Linus Health's board of directors. Butler brings decades of healthcare leadership and ...
